Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-paliperidone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 14C-paliperidone | DRUG | - |
Inclusion Criteria: * Dextromethorphan metabolic ratio of \>0.345 (poor metabolizer) or \<0.0255 (extensive metabolizer) * Body Mass Index: (weight \[kg\]/height \[m\]2) between 20 and 28 kg/m2, inclusive * Volunteers must have signed an informed consent document indicating that they understand the...
14C-paliperidone is an investigational small molecule being studied for use in schizophrenia. It is a radiolabeled form of paliperidone, used in clinical research to track the drug's plasma concentrations, metabolism, and excretion after a single oral dose. It is currently in Phase 1 clinical development.
14C-paliperidone is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is in Phase 1 clinical development for the treatment of schizophrenia.
14C-paliperidone is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 study has been completed, which evaluated the drug's plasma concentrations, metabolism, and excretion after a single oral dose in healthy male volunteers.
14C-paliperidone has one completed clinical trial, registered as NCT00796029. The study, titled 'A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose,' was a Phase 1, uncontrolled trial that enrolled 5 healthy male volunteers aged 40 years and older.
14C-paliperidone is a radiolabeled form of paliperidone, meaning it contains a radioactive carbon isotope (14C) used to trace the drug's behavior in the body. It is used in research to study how paliperidone is absorbed, metabolized, and excreted, rather than as a therapeutic treatment itself.